Sanguine Corporation, Inc. (SGNC.OB) – Working to Revive a Lost Medical Product
Based in Pasadena, CA, Sanguine Corporation develops and markets medical products derived from chemical compounds known as perfluorocarbons (PFCs). More specifically, the company develops a PFC emulsion, Fluosol, which is the only artificial "blood substitute" approved by the FDA to date for medical purposes. Developed in part by Dr. Thomas Drees, current CEO of Sanguine, Fluosol serves as an excellent dissolving medium for oxygen. Due to difficulties with maintaining the environment in which the emulsion is stored, widespread use of the original compound was discontinued in the early nineties. Sanguine uses a second generation adaptation of Fluosol to produce PHER…